AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00624598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART
Description: Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
Study NCT02630615 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Whole blood will be collected using standard phlebotomy procedures
Study NCT02324101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hsp90
Description: Detect plasma Hsp90α concentration
Study NCT00840112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement
Description: 400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
Study NCT03216226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon Analog
Study NCT03216226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: Native Glucagon
Study NCT01574469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)
Description: 1 = Intervention 1 (2 test products / day)
Study NCT01574469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Low fat fermented dairy product (control)
Description: 2 = Intervention 2 (2 control products/day)
Study NCT01213628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified warmed CO2
Description: Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
Study NCT02557139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil Tablet
Study NCT02557139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil Capsule
Study NCT04058964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Hyaluronidase PH20
Description: Given SC
Study NCT04058964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01287702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed feeding
Description: patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
Study NCT01287702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dealyed feeding
Description: patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
Study NCT01287702 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
Study NCT04569565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX catheter
Description: Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
Study NCT02503761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem.
Description: Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
Study NCT04668755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Charcot Restraint Orthotic Walker 3d printed sole
Description: The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) .
Study NCT04668755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Generic Charcot Restraint orthotic walker
Description: It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
Study NCT01519921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
Study NCT03327207 — intervention group
Intervention type: OTHER
Intervention: Non Interventional
Description: Non Interventional
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg once weekly
Description: Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide 2000 mg twice weekly
Description: Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as 250 milligram per square meter (mg/m\^2) as infusion (initial starting dose of 400 mg/m\^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m\^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Description: 5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Description: 5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m\^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
Study NCT00705016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m\^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
Study NCT02382432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine 0.4mg/kg
Description: 2ml intravenous bolus slowly injected in 2minutes.
Study NCT02382432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2ml intravenous bolus slowly injected in 2minutes
Study NCT00588107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Intervention
Description: Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
Study NCT00588107 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: print materials
Description: tailored print materials designed to aid in smoking reduction and cessation
Study NCT02289157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
Study NCT02902562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast Enhanced Ultrasound (CEUS)
Description: An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
Study NCT02902562 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
Study NCT01523106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: dietary supplement
Study NCT01523106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
Study NCT01588730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
Study NCT01588730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available Static Night splint
Description: A commericially avilable static night splint will be worn for 4-6 hours during rest.
Study NCT02416206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: BeEAM
Study NCT03177655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided Imagery meditation
Study NCT03177655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Journaling
Description: Keeping a journal
Study NCT05633758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
Study NCT05633758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
Study NCT00843219 — intervention group
Intervention type: PROCEDURE
Intervention: PET/CT Scan
Description: PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
Study NCT02846025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and capsule of oil hazel
Description: rich diet aministracao folate and capsule of oil hazel
Study NCT02846025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and placebo
Description: rich diet aministracao folate and placebo
Study NCT02846025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: antioxidant and placebo
Description: antioxidant diet (90μg folate) and placebo capsule
Study NCT01666028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceD or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
Study NCT01666028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with real-time CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study NCT01656408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150
Study NCT01656408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Study NCT01538095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies
Study NCT01538095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01538095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01538095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study NCT00232752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4.0 CYPHER Sirolimus-Eluting Coronary Stent
Description: 4.0 CYPHER Sirolimus-Eluting Coronary Stent
Study NCT03088956 — intervention group
Intervention type: OTHER
Intervention: Assessments
Description: Cognitive, Behavioral and Functional as described in the Outcome Measures
Study NCT02869464 — intervention group
Intervention type: OTHER
Intervention: Imaging-Ultrasound
Description: Abdominal Ultrasound
Study NCT02869464 — intervention group
Intervention type: OTHER
Intervention: Imaging-MRA
Description: Non-contrast Enhanced Magnetic Resonance Angiogram
Study NCT02869464 — intervention group
Intervention type: GENETIC
Intervention: DNA, RNA testing
Description: To test for the co-prevalence of shared genetic markers in afflicted populations.
Study NCT01721044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01721044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01721044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Participants will continue to take background cDMARD therapy throughout study.
Study NCT01721044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cDMARD
Description: Participants will continue to take background cDMARD therapy throughout study.
Study NCT01623453 — intervention group
Intervention type: BIOLOGICAL
Intervention: Autologous adipose derived stem cells(low dose group)
Description: low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study NCT01623453 — intervention group
Intervention type: BIOLOGICAL
Intervention: Autologous adipose derived stem cells(high dose group)
Description: high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study NCT02436629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich concentrated beetroot juice
Description: James White, Beet It Sport Shot, 70ml (Standard)
Study NCT02436629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted concentrated red beetroot juice
Description: Beet It Sport Shot, 70ml (Placebo)
Study NCT01434199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UPD guidance
Description: A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
Study NCT00612144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin fixed combination
Description: Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG
Study NCT00612144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl
Description: Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG
Study NCT01523912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of dysplastic mucosa (HALO)
Description: Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
Study NCT00997308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral, for 4 weeks
Study NCT00997308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01621269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Study NCT03483857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
Study NCT02039141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Every Little Step Counts Intervention
Description: Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc.
Study NCT03136510 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban 5 mg
Description: Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month
Study NCT03052062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipidrive
Description: LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day